08.01.24 -- First AI Antibody in Humans, Programmable mRNA, Tumor-Infiltrating Lymphocytes and more new episodes!

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. 

Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases.

Claris Bio CEO Clarke Atwell acknowledges that it's not the first to bring topically administered biologic therapies to the front of the eye, but if successful in the clinic, its Neurotrophic Keratitis candidate will vastly improve the patient experience. Atwell joins this episode of the Business of Biotech to explain further. 

Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three-phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. President and CEO Eamonn Hobbs is confident the company will succeed. Learn why in this episode.

Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. Aron Knickerbocker describes his strategically orchestrated career path, from his early days in the labs at Bristol-Myers Squibb and Genentech to his leadership of Aulos Bioscience, a company that boasts the first AI-generated antibody in human clinical trials.

While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash their teeth, and question life choices, then-19-year-old Enrique Diloné ate those classes for lunch. They inspired him to earn a Seton Hall Ph.D. in chemistry and to go to work as a big bio research scientist. Along the way, Dr. Diloné got bit by the biotech business bug.